Wall St. provides estimates for future stock prices of Eli Lilly from 2026 to 2030 based on projected revenue and net income.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.5% in the afternoon session after the U.S.

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...

UBS initiated coverage with a ‘Buy’ rating and set a $1,250 price target, citing confidence in Lilly’s obesity execution.

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...

Eli Lilly is riding the wave of a booming weight management market. Eli Lilly's tirzepatide, sold under the brand names ...

Eli Lilly stock reached an all-time high of 1113.03 USD, marking a significant milestone for the pharmaceutical giant. This achievement reflects a robust 41.51% increase over the past year, ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and ...

Eli Lilly and Company’s LLY stock has risen 18% in a month, driven mainly by a stellar third-quarter performance. Also, earlier this month, President Trump announced deals with Lilly and rival Novo ...

Eli Lilly (LLY) downgraded to Sell as obesity-drug competition and pricing pressure rise; stretched valuation boosts downside ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...